Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Protection Motivation Theory-Based Education for Infectious Disease Prevention in Primary Care

NCT07790367 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-27

Condition(s) studied

Infectious Disease Prevention

Investigational drug(s) / intervention(s)

Protection Motivation Theory-Based Educational Program

Protection Motivation Theory-Based Educational Program: Participants in the intervention group will receive a face-to-face educational program based on Protection Motivation Theory. The program will cover infectious disease transmission routes, prevention methods, hand hygiene, mask use, environmental hygiene, maintenance of immunity, risk awareness, and protective health behaviors. The intervention is designed to enhance threat appraisal and coping appraisal related to infectious disease prevention and to promote protective health behaviors.

Study summary

This study aims to evaluate the effect of a Protection Motivation Theory-based educational intervention on infectious disease perception, risk awareness, and protective health behaviors among adults attending primary care services. Participants will be assigned to an intervention group or a control group. The intervention group will receive a face-to-face educational program based on Protection Motivation Theory, while the control group will continue to receive routine health services without an additional educational intervention during the study period. Outcomes will be assessed at baseline and at Week 4 using validated self-report measures.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Being 18 years of age or older. * Being registered with and receiving services from the family health center where the study is conducted. * Being able to communicate in Turkish. * Voluntarily agreeing to participate in the study. * Being able to complete the study questionnaires and participate in the educational intervention. Exclusion Criteria: * Having a condition that prevents effective communication or participation in the educational intervention. * Declining to participate or withdrawing consent at any stage of the study. * Failing to complete the required pre-intervention or post-intervention assessments.

Primary outcome measure(s)

  • Change in Communicable Diseases Risk Awareness and Protection — Baseline and Week 4
    Communicable disease risk awareness and protection will be assessed using the Communicable Diseases Risk Awareness and Protection Scale (CDRAPS). The scale consists of 36 items rated on a 5-point Likert scale, with total scores ranging from 36 to 180. Higher scores indicate higher levels of communicable disease risk awareness and protection. Change in total score from baseline to Week 4 will be evaluated.
  • Change in Perception Toward Infectious Diseases — Baseline and Week 4
    Perception toward infectious diseases will be assessed using the Perception Scale for Infectious Diseases. The scale consists of 34 items rated on a 5-point Likert scale, with total scores ranging from 34 to 170. Higher scores indicate a more positive perception toward infectious diseases. Change in total score from baseline to Week 4 will be evaluated.
  • Change in Preventive Health Behaviors for Emerging Infectious Diseases — Baseline and Week 4
    Preventive health behaviors will be assessed using the Turkish version of the Emerging Infectious Diseases Preventive Health Behavior Scale (EID-PHB-T-30). The scale consists of 30 items rated on a 5-point Likert scale, with total scores ranging from 30 to 150. Higher scores indicate higher levels of preventive health behaviors against emerging infectious diseases. Change in total score from baseline to Week 4 will be evaluated.

Trial sites (1)

FacilityCityRegionStatus
Van Yuzuncu Yil University Van Van
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07790367 on ClinicalTrials.gov ↗ ← All trials in Turkey